AAIC 2024 | Highlights from AAIC 2024: tau-PET harmonization and the DIAN-TU trial

Cécile Tissot, PhD, University of California, Berkeley, CA, discusses highlights from this year’s AAIC meeting, including a session focused on tau-positron emission tomography (PET) harmonization in Alzheimer’s disease (AD). She also mentions the DIAN-TU trial (NCT01760005), which has shown favorable outcomes in patients treated with gantenerumab. This interview took place at the Alzheimer’s Association International Conference® (AAIC) 2024 in Philadelphia, PA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.